Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody

@inproceedings{Bilen2016AcuteRW,
  title={Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody},
  author={Mehmet Asim Bilen and Sumit K. Subudhi and Jianjun Gao and Nizar M. Tannir and S M Tu and P Sharma},
  booktitle={Journal for immunotherapy of cancer},
  year={2016}
}
BACKGROUND Immune checkpoint inhibitors have revolutionized cancer therapy since these drugs target inhibitory pathways on T cells, which result in durable anti-tumor immune responses and significant overall survival for a subset of cancer patients. These drugs can also lead to toxicities, which require additional research to identify mechanisms of toxicities and biomarkers that can help to identify patients who will develop immune-related adverse events. CASE PRESENTATION We describe the… CONTINUE READING